Tandem Diabetes Care (TNDM)
(Delayed Data from NSDQ)
$37.50 USD
+0.62 (1.68%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $37.49 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Price, Consensus and EPS Surprise
TNDM 37.50 +0.62(1.68%)
Will TNDM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TNDM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TNDM
Tandem Diabetes (TNDM) Q2 Earnings Beat, '24 View Raised
Tandem Diabetes Care (TNDM) Reports Q2 Earnings: What Key Metrics Have to Say
TNDM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Tops Revenue Estimates
Inari Medical, Inc. (NARI) Reports Q2 Loss, Tops Revenue Estimates
Here's How Thermo Fisher (TMO) is Placed Ahead of Q2 Earnings
Other News for TNDM
Critical Insights From Tandem Diabetes Care Analyst Ratings: What You Need To Know
Analysts’ Top Healthcare Picks: Xtant Medical Holdings (XTNT), Tandem Diabetes Care (TNDM)
Disney downgraded, Arm upgraded: Wall Street's top analyst calls
Tandem Diabetes Care: A Strong Buy on Market Positioning and Growth Prospects
Tandem Diabetes initiated with bullish view at Canaccord, here's why